SIGA Technologies, Inc. (NASDAQ:SIGA - Free Report) - Equities research analysts at Edison Inv. Res issued their FY2024 EPS estimates for SIGA Technologies in a note issued to investors on Monday, November 18th. Edison Inv. Res analyst J. Prakash anticipates that the company will post earnings per share of $1.04 for the year. Edison Inv. Res also issued estimates for SIGA Technologies' FY2025 earnings at $1.25 EPS.
SIGA Technologies (NASDAQ:SIGA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.02 EPS for the quarter. The business had revenue of $10.01 million during the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%.
SIGA Technologies Price Performance
SIGA traded up $0.02 during midday trading on Thursday, hitting $6.27. 322,573 shares of the company's stock traded hands, compared to its average volume of 881,154. SIGA Technologies has a one year low of $4.26 and a one year high of $12.83. The company has a market cap of $447.68 million, a PE ratio of 5.23 and a beta of 0.89. The stock's fifty day simple moving average is $7.06 and its 200-day simple moving average is $7.90.
Hedge Funds Weigh In On SIGA Technologies
Institutional investors have recently modified their holdings of the company. Larson Financial Group LLC bought a new position in shares of SIGA Technologies in the third quarter valued at approximately $30,000. DekaBank Deutsche Girozentrale bought a new position in SIGA Technologies during the second quarter worth $40,000. Bayesian Capital Management LP bought a new position in SIGA Technologies during the first quarter worth $97,000. EP Wealth Advisors LLC bought a new position in SIGA Technologies during the third quarter worth $82,000. Finally, Lazard Asset Management LLC acquired a new stake in SIGA Technologies during the first quarter worth $105,000. Institutional investors own 55.40% of the company's stock.
SIGA Technologies Company Profile
(
Get Free Report)
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Recommended Stories
Before you consider SIGA Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SIGA Technologies wasn't on the list.
While SIGA Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
